Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 5/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.31 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21923172 | 0.80 | MAP4K4 (0.46) | MAP4K4ADRA1ALRRK2HTR2BADRA2A | |
| SCHEMBL9761882 | 0.80 | MAP4K4 (0.46) | MAP4K4ADRA1ALRRK2HTR2BADRA2A | |
| SCHEMBL15551483 | 0.75 | HPGDS (0.54) | HTR2B | |
| SCHEMBL15550395 | 0.73 | HTR2B (0.50) | MAP4K4ADRA1ALRRK2HTR2B | |
| SCHEMBL10845973 | 0.73 | MAP4K4 (0.42) | MAP4K4ADRA1ALRRK2HTR2BADRA2A | |
| SCHEMBL1494449 | 0.73 | — | — | |
| SCHEMBL184451 | 0.73 | ADRA1A (0.55) | MAP4K4ADRA1AHTR2BADRA2AADRA1D | |
| SCHEMBL1133528 | 0.71 | ADRA1A (0.53) | MAP4K4ADRA1AHTR2BADRA2AADRA1D | |
| SCHEMBL7856564 | 0.71 | ADRA1A (0.53) | MAP4K4ADRA1AHTR2BADRA2AADRA1D | |
| SCHEMBL724530 | 0.71 | ADRA1A (0.53) | MAP4K4ADRA1AHTR2BADRA2AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9382241-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | DPYD, FANCD2, RECQL | MAP4K4 700/4885ADRA1A 1749/4885LRRK2 1376/4885 |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | MAP4K4 662/4885ADRA1A 1143/4885LRRK2 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.